{
    "eid": "2-s2.0-85091088225",
    "title": "Evaluation of intravenous fosfomycin disodium dosing regimens in critically ill patients for treatment of carbapenem-resistant enterobacterales infections using monte carlo simulation",
    "cover-date": "2020-09-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Microbiology",
            "@code": "2404",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Biochemistry",
            "@code": "1303",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology, Toxicology and Pharmaceutics (all)",
            "@code": "3000",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Microbiology (medical)",
            "@code": "2726",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Carbapenem-resistant Enterobacterales",
        "Critically ill patients",
        "Dosing regimens",
        "Intravenous fosfomycin disodium",
        "Pharmacokinetics/ pharmacodynamics"
    ],
    "authors": [
        "Pannee Leelawattanachai",
        "Thitima Wattanavijitkul",
        "Taniya Paiboonvong",
        "Rongpong Plongla",
        "Tanittha Chatsuwan",
        "Sang Usayaporn",
        "Wichit Nosoongnoen",
        "Preecha Montakantikul"
    ],
    "citedby-count": 9,
    "ref-count": 38,
    "ref-list": [
        "Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-ProducingEnterobacteriaceae",
        "Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options",
        "Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: What is the evidence on dosing regimens?",
        "New perspctives for reassessing fosfomycin: Applicability in current clinical practice",
        "ZTI-01 (fosfomycin for injection) in the treatment of hospitalized patients with complicated urinary tract infections",
        "Parenteral Fosfomycin for the Treatment of Multidrug Resistant Bacterial Infections: The Rise of the Epoxide",
        "Population pharmacokinetics and pharmacodynamics of fosfomycin in non\u2013critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli",
        "Population Pharmacokinetic (PPK) Analysis of ZTI-01 (Fosfomycin for Injection) Using Data from Healthy Subjects and Patients with Complicated Urinary Tract Infections (cUTI)",
        "Population Pharmacokinetics of Fosfomycin in Critically Ill Patients",
        "Adverse events associated with intravenous fosfomycin",
        "The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments",
        "In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa",
        "Synergistic Activity of Colistin/Fosfomycin Combination against Carbapenemase-Producing Klebsiella pneumoniae in an In Vitro Pharmacokinetic/Pharmacodynamic Model",
        "Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents",
        "Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selection",
        "The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace",
        "New microbiological aspects of fosfomycin",
        "Update on fosfomycin-modified genes in Enterobacteriaceae",
        "Fosfomycin",
        "Discrepancies in fosfomycin susceptibility testing of KPC-producing Klebsiella pneumoniae with various commercial methods",
        "1546. Incidence of Carbapenemase-Producing Klebsiella pneumoniae Colonization in Hematopoietic Stem Cell Transplant Recipients in King Chulalongkorn Memorial Hospital (KCMH), Thailand",
        "Rapid Detection of Carbapenmase-Producing Klebsiella pneumoniae (CPK) Directly from Respiratory Secretion and Clinical Characteristics of Patients with CPK from a 1,200-Bed Tertiary Care Hospital in Thailand",
        "Antibiotic susceptibility and carbapenemase genes in carbapenem resistant Enterobacteriaceae (CRE) isolated from hospitalized patients at Siriraj Hospital",
        "Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae from Bangkok, Thailand, and Their Detection by the Carba NP and Modified Carbapenem Inactivation Method Tests",
        "The occurrence of carbapenem-resistant Klebsiella pneumoniae (CRKP) isolated from patients in the medicine ward, Songklanagarind Hospital",
        "Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae",
        "Deciphering pharmacokinetics and pharmacodynamics of fosfomycin",
        "Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: A prospective evaluation",
        "Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria",
        "Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial",
        "Phenotypic Antibiotic Resistance in ZEUS: A Multi-center, Randomized, Double-Blind Phase 2/3 Study of ZTI-01 vs. Piperacillin-Tazobactam (P-T) in the Treatment of Patients with Complicated Urinary Tract Infections (cUTI) Including Acute Pyelonephritis (AP)"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Pathum Thani",
            "@id": "60023366",
            "affilname": "Rangsit University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60023366",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60020352",
            "affilname": "Vajira Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60020352",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nakhon Pathom",
            "@id": "60012718",
            "affilname": "Mahidol University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012718",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "King Chulalongkorn Memorial Hospital"
    ]
}